This study is testing a new treatment for certain blood cancers (hematological malignancies) that have come back or are not responding to standard treatments. The treatment involves giving you special immune cells called CAR.5/IL15-transduced CB-NK cells, along with chemotherapy drugs called Fludarabine Phosphate and Cyclophosphamide. Researchers want to find out how safe this treatment is, what dose works best, and how well it shrinks the cancer. To join, your cancer must show a certain level of a marker called CD5, and you must meet other specific criteria for your type of blood cancer. The main goal is to track any side effects you might experience.

Study design

This is an interventional study planning to enroll 64 participants. It is a Phase I/II study, meaning it will first look at safety and then at effectiveness.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed through study completion, which is an average of 1 year, to assess treatment-related side effects.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.